{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T03:53:24Z","timestamp":1784865204623,"version":"3.55.0"},"reference-count":71,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2023,11,18]],"date-time":"2023-11-18T00:00:00Z","timestamp":1700265600000},"content-version":"vor","delay-in-days":17,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Johann Wolfgang Goethe-Universit\u00e4t, Frankfurt am Main"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["CNS Drugs"],"published-print":{"date-parts":[[2023,11]]},"DOI":"10.1007\/s40263-023-01049-w","type":"journal-article","created":{"date-parts":[[2023,11,18]],"date-time":"2023-11-18T15:02:22Z","timestamp":1700319742000},"page":"993-1008","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Trends and Differences in Status Epilepticus Treatment of Children and Adults Over 10 Years: A Comparative Study of Medical Records (2012\u20132021) from a University Hospital in Germany"],"prefix":"10.1007","volume":"37","author":[{"given":"Leonore","family":"Purwien","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanne","family":"Schubert-Bast","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Kieslich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael W.","family":"Ronellenfitsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Merker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcus","family":"Czabanka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8226-1674","authenticated-orcid":false,"given":"Laurent M.","family":"Willems","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3989-7471","authenticated-orcid":false,"given":"Felix","family":"Rosenow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6288-9915","authenticated-orcid":false,"given":"Adam","family":"Strzelczyk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,11,18]]},"reference":[{"key":"1049_CR1","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.seizure.2019.10.003","volume":"75","author":"S Shorvon","year":"2020","unstructured":"Shorvon S, Sen A. What is status epilepticus and what do we know about its epidemiology? Seizure. 2020;75:131\u20136. https:\/\/doi.org\/10.1016\/j.seizure.2019.10.003.","journal-title":"Seizure."},{"issue":"3","key":"1049_CR2","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1007\/s12028-013-9935-x","volume":"20","author":"BS Dham","year":"2014","unstructured":"Dham BS, Hunter K, Rincon F. The epidemiology of status epilepticus in the United States. Neurocrit Care. 2014;20(3):476\u201383. https:\/\/doi.org\/10.1007\/s12028-013-9935-x.","journal-title":"Neurocrit Care"},{"key":"1049_CR3","doi-asserted-by":"publisher","unstructured":"Willems LM, Rosenow F, Strzelczyk A. Therapeutic options for patients with status epilepticus in old age. Z Epileptol. 2022;35:117\u201322. https:\/\/doi.org\/10.1007\/s10309-022-00544-2.","DOI":"10.1007\/s10309-022-00544-2"},{"key":"1049_CR4","doi-asserted-by":"publisher","DOI":"10.1016\/j.yebeh.2019.106720","volume":"2","author":"M Leitinger","year":"2020","unstructured":"Leitinger M, Trinka E, Zimmermann G, Granbichler CA, Kobulashvili T, Siebert U. Epidemiology of status epilepticus in adults: apples, pears, and oranges\u2014a critical review. Epilepsy Behav E&B. 2020;2:106720. https:\/\/doi.org\/10.1016\/j.yebeh.2019.106720.","journal-title":"Epilepsy Behav E&B."},{"issue":"6","key":"1049_CR5","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1046\/j.1528-1157.2001.01101.x","volume":"42","author":"S Knake","year":"2001","unstructured":"Knake S, Rosenow F, Vescovi M, Oertel WH, Mueller HH, Wirbatz A, et al. Incidence of status epilepticus in adults in Germany: a prospective, population-based study. Epilepsia. 2001;42(6):714\u20138. https:\/\/doi.org\/10.1046\/j.1528-1157.2001.01101.x.","journal-title":"Epilepsia"},{"key":"1049_CR6","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/j.seizure.2019.10.006","volume":"75","author":"AA Crawshaw","year":"2020","unstructured":"Crawshaw AA, Cock HR. Medical management of status epilepticus: emergency room to intensive care unit. Seizure. 2020;75:145\u201352. https:\/\/doi.org\/10.1016\/j.seizure.2019.10.006.","journal-title":"Seizure."},{"key":"1049_CR7","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2019.1268","author":"A Neligan","year":"2019","unstructured":"Neligan A, Noyce AJ, Gosavi TD, Shorvon SD, Kohler S, Walker MC. Change in mortality of generalized convulsive status epilepticus in high-income countries over time: a systematic review and meta-analysis. JAMA Neurol. 2019;76:897\u2013905. https:\/\/doi.org\/10.1001\/jamaneurol.2019.1268.","journal-title":"JAMA Neurol"},{"issue":"3","key":"1049_CR8","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1002\/ana.25416","volume":"85","author":"C Kellinghaus","year":"2019","unstructured":"Kellinghaus C, Rossetti AO, Trinka E, Lang N, May TW, Unterberger I, et al. Factors predicting cessation of status epilepticus in clinical practice: data from a prospective observational registry (SENSE). Ann Neurol. 2019;85(3):421\u201332. https:\/\/doi.org\/10.1002\/ana.25416.","journal-title":"Ann Neurol"},{"issue":"6","key":"1049_CR9","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1001\/jamaneurol.2022.0609","volume":"79","author":"LE Roberg","year":"2022","unstructured":"Roberg LE, Monsson O, Kristensen SB, Dahl SM, Ulvin LB, Heuser K, et al. Prediction of long-term survival after status epilepticus using the ACD Score. JAMA Neurol. 2022;79(6):604\u201313. https:\/\/doi.org\/10.1001\/jamaneurol.2022.0609.","journal-title":"JAMA Neurol"},{"key":"1049_CR10","doi-asserted-by":"crossref","unstructured":"Rosenow F, Weber J. Status epilepticus im Erwachsenenalter, S2k-Leitlinie. Deutsche Gesellschaft f\u00fcr Neurologie (Hrsg), Leitlinien f\u00fcr Diagnostik und Therapie in der Neurologie. 2020.","DOI":"10.1007\/s00115-020-01036-2"},{"issue":"1","key":"1049_CR11","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/s12028-012-9695-z","volume":"17","author":"GM Brophy","year":"2012","unstructured":"Brophy GM, Bell R, Claassen J, Alldredge B, Bleck TP, Glauser T, et al. Guidelines for the evaluation and management of status epilepticus. Neurocrit Care. 2012;17(1):3\u201323. https:\/\/doi.org\/10.1007\/s12028-012-9695-z.","journal-title":"Neurocrit Care"},{"issue":"1","key":"1049_CR12","doi-asserted-by":"publisher","first-page":"48","DOI":"10.5698\/1535-7597-16.1.48","volume":"16","author":"T Glauser","year":"2016","unstructured":"Glauser T, Shinnar S, Gloss D, Alldredge B, Arya R, Bainbridge J, et al. Evidence-based guideline: treatment of convulsive status epilepticus in children and adults: report of the Guideline Committee of the American Epilepsy Society. Epilepsy Curr. 2016;16(1):48\u201361. https:\/\/doi.org\/10.5698\/1535-7597-16.1.48.","journal-title":"Epilepsy Curr."},{"issue":"7","key":"1049_CR13","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1056\/NEJMoa1107494","volume":"366","author":"R Silbergleit","year":"2012","unstructured":"Silbergleit R, Durkalski V, Lowenstein D, Conwit R, Pancioli A, Palesch Y, et al. Intramuscular versus intravenous therapy for prehospital status epilepticus. N Engl J Med. 2012;366(7):591\u2013600. https:\/\/doi.org\/10.1056\/NEJMoa1107494.","journal-title":"N Engl J Med"},{"issue":"9","key":"1049_CR14","doi-asserted-by":"publisher","first-page":"CD003723","DOI":"10.1002\/14651858.CD003723.pub3","volume":"10","author":"M Prasad","year":"2014","unstructured":"Prasad M, Krishnan PR, Sequeira R, Al-Roomi K. Anticonvulsant therapy for status epilepticus. Cochrane Datab Syst Rev. 2014;10(9):CD003723. https:\/\/doi.org\/10.1002\/14651858.CD003723.pub3.","journal-title":"Cochrane Datab Syst Rev."},{"issue":"2","key":"1049_CR15","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1111\/epi.12905","volume":"56","author":"RD Welch","year":"2015","unstructured":"Welch RD, Nicholas K, Durkalski-Mauldin VL, Lowenstein DH, Conwit R, Mahajan PV, et al. Intramuscular midazolam versus intravenous lorazepam for the prehospital treatment of status epilepticus in the pediatric population. Epilepsia. 2015;56(2):254\u201362. https:\/\/doi.org\/10.1111\/epi.12905.","journal-title":"Epilepsia"},{"issue":"13","key":"1049_CR16","doi-asserted-by":"publisher","first-page":"1499","DOI":"10.1007\/s40265-015-0454-2","volume":"75","author":"E Trinka","year":"2015","unstructured":"Trinka E, Hofler J, Leitinger M, Brigo F. Pharmacotherapy for status epilepticus. Drugs. 2015;75(13):1499\u2013521. https:\/\/doi.org\/10.1007\/s40265-015-0454-2.","journal-title":"Drugs"},{"issue":"4","key":"1049_CR17","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1684\/epd.2019.1083","volume":"21","author":"E Perucca","year":"2019","unstructured":"Perucca E. Antiepileptic drugs: evolution of our knowledge and changes in drug trials. Epilept Disord. 2019;21(4):319\u201329. https:\/\/doi.org\/10.1684\/epd.2019.1083.","journal-title":"Epilept Disord Int Epilep J Videotape."},{"issue":"11","key":"1049_CR18","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1007\/s40262-013-0087-0","volume":"52","author":"PN Patsalos","year":"2013","unstructured":"Patsalos PN. Drug interactions with the newer antiepileptic drugs (AEDs)\u2013part 1: pharmacokinetic and pharmacodynamic interactions between AEDs. Clin Pharmacokinet. 2013;52(11):927\u201366. https:\/\/doi.org\/10.1007\/s40262-013-0087-0.","journal-title":"Clin Pharmacokinet"},{"issue":"22","key":"1049_CR19","doi-asserted-by":"publisher","first-page":"2103","DOI":"10.1056\/NEJMoa1905795","volume":"381","author":"J Kapur","year":"2019","unstructured":"Kapur J, Elm J, Chamberlain JM, Barsan W, Cloyd J, Lowenstein D, et al. Randomized trial of three anticonvulsant medications for status epilepticus. N Engl J Med. 2019;381(22):2103\u201313. https:\/\/doi.org\/10.1056\/NEJMoa1905795.","journal-title":"N Engl J Med"},{"key":"1049_CR20","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.seizure.2019.11.007","volume":"74","author":"SS Chu","year":"2020","unstructured":"Chu SS, Wang HJ, Zhu LN, Xu D, Wang XP, Liu L. Therapeutic effect of intravenous levetiracetam in status epilepticus: a meta-analysis and systematic review. Seizure. 2020;74:49\u201355. https:\/\/doi.org\/10.1016\/j.seizure.2019.11.007.","journal-title":"Seizure."},{"issue":"Pt B","key":"1049_CR21","doi-asserted-by":"publisher","DOI":"10.1016\/j.yebeh.2019.106466","volume":"101","author":"F Brigo","year":"2019","unstructured":"Brigo F, Del Giovane C, Nardone R, Trinka E, Lattanzi S. Intravenous antiepileptic drugs in adults with benzodiazepine-resistant convulsive status epilepticus: a systematic review and network meta-analysis. Epilepsy Behav. 2019;101(Pt B): 106466. https:\/\/doi.org\/10.1016\/j.yebeh.2019.106466.","journal-title":"Epilepsy Behav"},{"issue":"8","key":"1049_CR22","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1007\/s40263-019-00652-0","volume":"33","author":"F Brigo","year":"2019","unstructured":"Brigo F, Lattanzi S, Nardone R, Trinka E. Intravenous brivaracetam in the treatment of status epilepticus: a systematic review. CNS Drugs. 2019;33(8):771\u201381. https:\/\/doi.org\/10.1007\/s40263-019-00652-0.","journal-title":"CNS Drugs"},{"issue":"5","key":"1049_CR23","doi-asserted-by":"publisher","first-page":"205","DOI":"10.2176\/nmc.ra.2015-0344","volume":"56","author":"R Hanaya","year":"2016","unstructured":"Hanaya R, Arita K. The new antiepileptic drugs: their neuropharmacology and clinical indications. Neurol Med Chir (Tokyo). 2016;56(5):205\u201320. https:\/\/doi.org\/10.2176\/nmc.ra.2015-0344.","journal-title":"Neurol Med Chir (Tokyo)"},{"issue":"9596","key":"1049_CR24","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1016\/S0140-6736(07)61602-X","volume":"370","author":"E von Elm","year":"2007","unstructured":"von Elm E, Altman DG, Egger M, Pocock SJ, Gotzsche PC, Vandenbroucke JP, et al. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Lancet. 2007;370(9596):1453\u20137. https:\/\/doi.org\/10.1016\/S0140-6736(07)61602-X.","journal-title":"Lancet"},{"issue":"10","key":"1049_CR25","doi-asserted-by":"publisher","first-page":"1515","DOI":"10.1111\/epi.13121","volume":"56","author":"E Trinka","year":"2015","unstructured":"Trinka E, Cock H, Hesdorffer D, Rossetti AO, Scheffer IE, Shinnar S, et al. A definition and classification of status epilepticus\u2014report of the ILAE Task Force on Classification of Status Epilepticus. Epilepsia. 2015;56(10):1515\u201323. https:\/\/doi.org\/10.1111\/epi.13121.","journal-title":"Epilepsia"},{"issue":"6","key":"1049_CR26","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1016\/S1474-4422(15)00042-3","volume":"14","author":"JP Betjemann","year":"2015","unstructured":"Betjemann JP, Lowenstein DH. Status epilepticus in adults. Lancet Neurol. 2015;14(6):615\u201324. https:\/\/doi.org\/10.1016\/S1474-4422(15)00042-3.","journal-title":"Lancet Neurol"},{"issue":"3","key":"1049_CR27","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1007\/s40265-017-0859-1","volume":"78","author":"M Holtkamp","year":"2018","unstructured":"Holtkamp M. Pharmacotherapy for refractory and super-refractory status epilepticus in adults. Drugs. 2018;78(3):307\u201326. https:\/\/doi.org\/10.1007\/s40265-017-0859-1.","journal-title":"Drugs"},{"key":"1049_CR28","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1016\/j.yebeh.2015.05.007","volume":"49","author":"M Leitinger","year":"2015","unstructured":"Leitinger M, Beniczky S, Rohracher A, Gardella E, Kalss G, Qerama E, et al. Salzburg consensus criteria for non-convulsive status epilepticus\u2013approach to clinical application. Epilepsy Behav. 2015;49:158\u201363. https:\/\/doi.org\/10.1016\/j.yebeh.2015.05.007.","journal-title":"Epilepsy Behav"},{"issue":"10","key":"1049_CR29","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1016\/S1474-4422(16)30137-5","volume":"15","author":"M Leitinger","year":"2016","unstructured":"Leitinger M, Trinka E, Gardella E, Rohracher A, Kalss G, Qerama E, et al. Diagnostic accuracy of the Salzburg EEG criteria for non-convulsive status epilepticus: a retrospective study. Lancet Neurol. 2016;15(10):1054\u201362. https:\/\/doi.org\/10.1016\/S1474-4422(16)30137-5.","journal-title":"Lancet Neurol"},{"issue":"4","key":"1049_CR30","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1111\/epi.13670","volume":"58","author":"RS Fisher","year":"2017","unstructured":"Fisher RS, Cross JH, French JA, Higurashi N, Hirsch E, Jansen FE, et al. Operational classification of seizure types by the International League Against Epilepsy: Position Paper of the ILAE Commission for Classification and Terminology. Epilepsia. 2017;58(4):522\u201330. https:\/\/doi.org\/10.1111\/epi.13670.","journal-title":"Epilepsia"},{"issue":"4","key":"1049_CR31","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1111\/epi.13709","volume":"58","author":"IE Scheffer","year":"2017","unstructured":"Scheffer IE, Berkovic S, Capovilla G, Connolly MB, French J, Guilhoto L, et al. ILAE classification of the epilepsies: position paper of the ILAE Commission for Classification and Terminology. Epilepsia. 2017;58(4):512\u201321. https:\/\/doi.org\/10.1111\/epi.13709.","journal-title":"Epilepsia"},{"issue":"6","key":"1049_CR32","doi-asserted-by":"publisher","first-page":"1398","DOI":"10.1111\/epi.17241","volume":"63","author":"N Specchio","year":"2022","unstructured":"Specchio N, Wirrell EC, Scheffer IE, Nabbout R, Riney K, Samia P, et al. International League Against Epilepsy classification and definition of epilepsy syndromes with onset in childhood: Position paper by the ILAE Task Force on Nosology and Definitions. Epilepsia. 2022;63(6):1398\u2013442. https:\/\/doi.org\/10.1111\/epi.17241.","journal-title":"Epilepsia"},{"issue":"5","key":"1049_CR33","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1001\/jamaneurol.2021.0520","volume":"78","author":"EL Guterman","year":"2021","unstructured":"Guterman EL, Betjemann JP, Aimetti A, Li JW, Wang Z, Yin D, et al. Association between treatment progression, disease refractoriness, and burden of illness among hospitalized patients with status epilepticus. JAMA Neurol. 2021;78(5):588\u201395. https:\/\/doi.org\/10.1001\/jamaneurol.2021.0520.","journal-title":"JAMA Neurol"},{"issue":"3","key":"1049_CR34","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1111\/ane.13363","volume":"143","author":"A Gutierrez-Viedma","year":"2021","unstructured":"Gutierrez-Viedma A, Parejo-Carbonell B, Romeral-Jimenez M, Sanz-Graciani I, Serrano-Garcia I, Cuadrado ML, et al. Therapy delay in status epilepticus extends its duration and worsens its prognosis. Acta Neurol Scand. 2021;143(3):281\u20139. https:\/\/doi.org\/10.1111\/ane.13363.","journal-title":"Acta Neurol Scand"},{"key":"1049_CR35","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.seizure.2019.11.003","volume":"74","author":"C Reindl","year":"2020","unstructured":"Reindl C, Sprugel MI, Sembill JA, Mueller TM, Hagen M, Gerner ST, et al. Influence of new versus traditional antiepileptic drugs on course and outcome of status epilepticus. Seizure. 2020;74:20\u20135. https:\/\/doi.org\/10.1016\/j.seizure.2019.11.003.","journal-title":"Seizure."},{"issue":"8","key":"1049_CR36","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1212\/WNL.0000000000000009","volume":"82","author":"R Sutter","year":"2014","unstructured":"Sutter R, Marsch S, Fuhr P, Kaplan PW, Ruegg S. Anesthetic drugs in status epilepticus: risk or rescue? A 6-year cohort study. Neurology. 2014;82(8):656\u201364. https:\/\/doi.org\/10.1212\/WNL.0000000000000009.","journal-title":"Neurology"},{"issue":"12","key":"1049_CR37","doi-asserted-by":"publisher","first-page":"2056","DOI":"10.1111\/epi.13584","volume":"57","author":"LM Kortland","year":"2016","unstructured":"Kortland LM, Alfter A, B\u00e4hr O, Carl B, Dodel R, Freiman TM, et al. Costs and cost-driving factors for acute treatment of adults with status epilepticus: a multicenter cohort study from Germany. Epilepsia. 2016;57(12):2056\u201366. https:\/\/doi.org\/10.1111\/epi.13584.","journal-title":"Epilepsia"},{"issue":"9","key":"1049_CR38","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1111\/dmcn.14900","volume":"63","author":"C Mitchell","year":"2021","unstructured":"Mitchell C, Chatterton Dickson L, Ramsay A, Mesalles-Naranjo O, Leonard P, Brand C, et al. Epidemiology and outcome of status epilepticus in children: a Scottish population cohort study. Dev Med Child Neurol. 2021;63(9):1075\u201384. https:\/\/doi.org\/10.1111\/dmcn.14900.","journal-title":"Dev Med Child Neurol"},{"key":"1049_CR39","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.seizure.2018.07.020","volume":"61","author":"LB Ulvin","year":"2018","unstructured":"Ulvin LB, Heuser K, Olsen KB, Tauboll E. Factors associated with refractoriness and outcome in an adult status epilepticus cohort. Seizure. 2018;61:111\u20138. https:\/\/doi.org\/10.1016\/j.seizure.2018.07.020.","journal-title":"Seizure."},{"issue":"1\u20132","key":"1049_CR40","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1016\/j.eplepsyres.2013.08.001","volume":"107","author":"K Rantsch","year":"2013","unstructured":"Rantsch K, Walter U, Wittstock M, Benecke R, Rosche J. Treatment and course of different subtypes of status epilepticus. Epilepsy Res. 2013;107(1\u20132):156\u201362. https:\/\/doi.org\/10.1016\/j.eplepsyres.2013.08.001.","journal-title":"Epilepsy Res"},{"key":"1049_CR41","doi-asserted-by":"publisher","unstructured":"Bauer K, Rosenow F, Knake S, Willems LM, K\u00e4mppi L, Strzelczyk A. Clinical characteristics and outcomes of patients with recurrent status epilepticus episodes. Neurol Res Pract. 2023;5(1):34. https:\/\/doi.org\/10.1186\/s42466-023-00261-9.","DOI":"10.1186\/s42466-023-00261-9"},{"key":"1049_CR42","doi-asserted-by":"publisher","unstructured":"Meyer S, Langer J, Poryo M, Bay JG, Wagenpfeil S, Heinrich B, et al. Epileptic Status in a PEDiatric cohort (ESPED) requiring intensive care treatment: A multicenter national two\u2010year prospective surveillance study. Epilepsia Open. 2023;8(2):411\u2013424. https:\/\/doi.org\/10.1002\/epi4.12707.","DOI":"10.1002\/epi4.12707"},{"issue":"3","key":"1049_CR43","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1007\/s40263-018-0509-5","volume":"32","author":"I Beuchat","year":"2018","unstructured":"Beuchat I, Novy J, Rossetti AO. Newer antiepileptic drugs for status epilepticus in adults: what\u2019s the evidence? CNS Drugs. 2018;32(3):259\u201367. https:\/\/doi.org\/10.1007\/s40263-018-0509-5.","journal-title":"CNS Drugs"},{"issue":"1","key":"1049_CR44","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.yebeh.2012.02.026","volume":"24","author":"L Jaques","year":"2012","unstructured":"Jaques L, Rossetti AO. Newer antiepileptic drugs in the treatment of status epilepticus: impact on prognosis. Epilepsy Behav. 2012;24(1):70\u20133. https:\/\/doi.org\/10.1016\/j.yebeh.2012.02.026.","journal-title":"Epilepsy Behav"},{"issue":"4","key":"1049_CR45","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1007\/s40263-017-0424-1","volume":"31","author":"I Beuchat","year":"2017","unstructured":"Beuchat I, Novy J, Rossetti AO. Newer antiepileptic drugs in status epilepticus: prescription trends and outcomes in comparison with traditional agents. CNS Drugs. 2017;31(4):327\u201334. https:\/\/doi.org\/10.1007\/s40263-017-0424-1.","journal-title":"CNS Drugs"},{"issue":"1","key":"1049_CR46","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1007\/s12028-013-9862-x","volume":"19","author":"L Kamppi","year":"2013","unstructured":"K\u00e4mppi L, Mustonen H, Soinila S. Analysis of the delay components in the treatment of status epilepticus. Neurocrit Care. 2013;19(1):10\u20138. https:\/\/doi.org\/10.1007\/s12028-013-9862-x.","journal-title":"Neurocrit Care"},{"issue":"1","key":"1049_CR47","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1007\/s12028-014-0016-6","volume":"22","author":"L Kamppi","year":"2015","unstructured":"K\u00e4mppi L, Mustonen H, Soinila S. Factors related to delays in pre-hospital management of status epilepticus. Neurocrit Care. 2015;22(1):93\u2013104. https:\/\/doi.org\/10.1007\/s12028-014-0016-6.","journal-title":"Neurocrit Care"},{"issue":"8","key":"1049_CR48","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1007\/s40263-018-0544-2","volume":"32","author":"J Kadel","year":"2018","unstructured":"Kadel J, Bauer S, Hermsen AM, Immisch I, Kay L, Klein KM, et al. Use of emergency medication in adult patients with epilepsy: a multicentre cohort study from Germany. CNS Drugs. 2018;32(8):771\u201381. https:\/\/doi.org\/10.1007\/s40263-018-0544-2.","journal-title":"CNS Drugs"},{"issue":"6","key":"1049_CR49","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1111\/j.1553-2712.2010.00751.x","volume":"17","author":"J McMullan","year":"2010","unstructured":"McMullan J, Sasson C, Pancioli A, Silbergleit R. Midazolam versus diazepam for the treatment of status epilepticus in children and young adults: a meta-analysis. Acad Emerg Med. 2010;17(6):575\u201382. https:\/\/doi.org\/10.1111\/j.1553-2712.2010.00751.x.","journal-title":"Acad Emerg Med"},{"issue":"9153","key":"1049_CR50","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1016\/S0140-6736(98)06425-3","volume":"353","author":"RC Scott","year":"1999","unstructured":"Scott RC, Besag FM, Neville BG. Buccal midazolam and rectal diazepam for treatment of prolonged seizures in childhood and adolescence: a randomised trial. Lancet. 1999;353(9153):623\u20136. https:\/\/doi.org\/10.1016\/S0140-6736(98)06425-3.","journal-title":"Lancet"},{"key":"1049_CR51","unstructured":"European Medicines Agency. EPAR summary for the public Buccolam EMA\/522148\/2011. 2011 [accessed 02\/28\/2023]; https:\/\/www.ema.europa.eu\/en\/documents\/overview\/buccolam-epar-summary-public_en.pdf."},{"key":"1049_CR52","unstructured":"Hessisches Ministerium f\u00fcr Soziales und Integration. Algorithmen zur Notfallversorgung, Lehrmeinung f\u00fcr die Notfallsanit\u00e4ter-Ausbildung an den hessischen Rettungsdienstschulen. 2021 [accessed 02\/25\/2023]; https:\/\/rettungsdienstschule-gelnhausen.de\/algorithmus\/Algorithmen-Notfallversorgung-NotSan.pdf."},{"issue":"12","key":"1049_CR53","doi-asserted-by":"publisher","first-page":"2413","DOI":"10.1002\/acn3.50932","volume":"6","author":"L Kay","year":"2019","unstructured":"Kay L, Merkel N, von Blomberg A, Willems LM, Bauer S, Reif PS, et al. Intranasal midazolam as first-line inhospital treatment for status epilepticus: a pharmaco-EEG cohort study. Ann Clin Transl Neurol. 2019;6(12):2413\u201325. https:\/\/doi.org\/10.1002\/acn3.50932.","journal-title":"Ann Clin Transl Neurol"},{"issue":"3","key":"1049_CR54","doi-asserted-by":"publisher","first-page":"fcad145","DOI":"10.1093\/braincomms\/fcad145","volume":"5","author":"A Mevius","year":"2023","unstructured":"Mevius A, Joeres L, Gille P, Molzan M, Foskett N, Wilke T, et al. Epidemiology, real-world treatment and mortality of patients with status epilepticus in Germany: insights from a large healthcare database. Brain Commun. 2023;5(3):fcad145. https:\/\/doi.org\/10.1093\/braincomms\/fcad145.","journal-title":"Brain Commun."},{"issue":"10","key":"1049_CR55","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.18515","volume":"13","author":"J Dell'Aquila","year":"2021","unstructured":"Dell\u2019Aquila J, Soti V. Treating status epilepticus: phenytoin versus levetiracetam. Cureus. 2021;13(10): e18515. https:\/\/doi.org\/10.7759\/cureus.18515.","journal-title":"Cureus."},{"issue":"4","key":"1049_CR56","doi-asserted-by":"publisher","first-page":"468","DOI":"10.3988\/jcn.2019.15.4.468","volume":"15","author":"N Noureen","year":"2019","unstructured":"Noureen N, Khan S, Khursheed A, Iqbal I, Maryam M, Sharib SM, et al. Clinical efficacy and safety of injectable levetiracetam versus phenytoin as second-line therapy in the management of generalized convulsive status epilepticus in children: an open-label randomized controlled trial. J Clin Neurol. 2019;15(4):468\u201372. https:\/\/doi.org\/10.3988\/jcn.2019.15.4.468.","journal-title":"J Clin Neurol"},{"key":"1049_CR57","doi-asserted-by":"publisher","DOI":"10.1111\/ene.15791","author":"I Kuffer","year":"2023","unstructured":"Kuffer I, Novy J, Rossetti AO. Status epilepticus prognosis following levetiracetam administration: analysis of loading doses. Eur J Neurol. 2023;30(7):1957\u201362. https:\/\/doi.org\/10.1111\/ene.15791.","journal-title":"Eur J Neurol"},{"issue":"10186","key":"1049_CR58","doi-asserted-by":"publisher","first-page":"2125","DOI":"10.1016\/S0140-6736(19)30724-X","volume":"393","author":"MD Lyttle","year":"2019","unstructured":"Lyttle MD, Rainford NEA, Gamble C, Messahel S, Humphreys A, Hickey H, et al. Levetiracetam versus phenytoin for second-line treatment of paediatric convulsive status epilepticus (EcLiPSE): a multicentre, open-label, randomised trial. Lancet. 2019;393(10186):2125\u201334. https:\/\/doi.org\/10.1016\/S0140-6736(19)30724-X.","journal-title":"Lancet"},{"issue":"10186","key":"1049_CR59","doi-asserted-by":"publisher","first-page":"2135","DOI":"10.1016\/S0140-6736(19)30722-6","volume":"393","author":"SR Dalziel","year":"2019","unstructured":"Dalziel SR, Borland ML, Furyk J, Bonisch M, Neutze J, Donath S, et al. Levetiracetam versus phenytoin for second-line treatment of convulsive status epilepticus in children (ConSEPT): an open-label, multicentre, randomised controlled trial. Lancet. 2019;393(10186):2135\u201345. https:\/\/doi.org\/10.1016\/S0140-6736(19)30722-6.","journal-title":"Lancet"},{"key":"1049_CR60","unstructured":"European Medicines Agency. Keppra Scientific Discussion Procedure No. EMEA\/H\/C\/277\/X\/46. 2006 [accessed 02\/16\/2023]; https:\/\/www.ema.europa.eu\/en\/documents\/scientific-discussion-variation\/keppra-h-c-277-x-0046-epar-scientific-discussion-extension_en.pdf."},{"issue":"2","key":"1049_CR61","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1097\/WCO.0000000000000659","volume":"32","author":"T Tomson","year":"2019","unstructured":"Tomson T, Battino D, Perucca E. Teratogenicity of antiepileptic drugs. Curr Opin Neurol. 2019;32(2):246\u201352. https:\/\/doi.org\/10.1097\/WCO.0000000000000659.","journal-title":"Curr Opin Neurol"},{"issue":"16","key":"1049_CR62","doi-asserted-by":"publisher","first-page":"e1824","DOI":"10.1212\/WNL.0000000000201099","volume":"99","author":"I Beuchat","year":"2022","unstructured":"Beuchat I, Rosenow F, Kellinghaus C, Trinka E, Unterberger I, Ruegg S, et al. Refractory status epilepticus: risk factors and analysis of intubation in the multicenter SENSE registry. Neurology. 2022;99(16):e1824\u201334. https:\/\/doi.org\/10.1212\/WNL.0000000000201099.","journal-title":"Neurology"},{"issue":"9","key":"1049_CR63","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1007\/s40263-022-00940-2","volume":"36","author":"R Kienitz","year":"2022","unstructured":"Kienitz R, Kay L, Beuchat I, Gelhard S, von Brauchitsch S, Mann C, et al. Benzodiazepines in the management of seizures and status epilepticus: a review of routes of delivery, pharmacokinetics, efficacy, and tolerability. CNS Drugs. 2022;36(9):951\u201375. https:\/\/doi.org\/10.1007\/s40263-022-00940-2.","journal-title":"CNS Drugs"},{"key":"1049_CR64","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.seizure.2023.07.010","volume":"111","author":"M Amengual-Gual","year":"2023","unstructured":"Amengual-Gual M, Sanchez Fernandez I, Vasquez A, Abend NS, Anderson A, Arya R, et al. Pediatric status epilepticus management by Emergency Medical Services (the pSERG cohort). Seizure. 2023;111:51\u20135. https:\/\/doi.org\/10.1016\/j.seizure.2023.07.010.","journal-title":"Seizure."},{"key":"1049_CR65","unstructured":"Diagnosis and management of epilepsy in adults. Scottish Intercollegiate Guidelines Network (SIGN). 2015. https:\/\/www.sign.ac.uk\/our-guidelines\/diagnosis-and-management-of-epilepsy-in-adults\/."},{"key":"1049_CR66","doi-asserted-by":"publisher","unstructured":"Fung EL, Fung BB, Subcommittee on the Consensus Statement of the Hong Kong Epilepsy S. Review and update of the Hong Kong Epilepsy Guideline on status epilepticus. Hong Kong Med J. 2017;23(1):67\u201373. https:\/\/doi.org\/10.12809\/hkmj166025.","DOI":"10.12809\/hkmj166025"},{"key":"1049_CR67","unstructured":"Steinhoff BJ, Bast T. Vademecum Antiepilepticum 2021\/2022. Deutsche Gesellschaft f\u00fcr Epileptologie e.V., Berlin."},{"issue":"1","key":"1049_CR68","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1093\/pch\/pxaa127","volume":"26","author":"KC McKenzie","year":"2021","unstructured":"McKenzie KC, Hahn CD, Friedman JN. Emergency management of the paediatric patient with convulsive status epilepticus. Paediatr Child Health. 2021;26(1):50\u201366. https:\/\/doi.org\/10.1093\/pch\/pxaa127.","journal-title":"Paediatr Child Health"},{"issue":"19","key":"1049_CR69","doi-asserted-by":"publisher","first-page":"e2683","DOI":"10.1212\/WNL.0000000000010828","volume":"95","author":"A Vasquez","year":"2020","unstructured":"Vasquez A, Gainza-Lein M, Abend NS, Amengual-Gual M, Anderson A, Arya R, et al. First-line medication dosing in pediatric refractory status epilepticus. Neurology. 2020;95(19):e2683\u201396. https:\/\/doi.org\/10.1212\/WNL.0000000000010828.","journal-title":"Neurology"},{"key":"1049_CR70","unstructured":"Wilfong A. Management of convulsive status epilepticus in children. UpToDate, Waltham, MA, USA. [accessed 02\/15\/2023] https:\/\/www.uptodate.com\/contents\/management-of-convulsive-status-epilepticus-in-children"},{"key":"1049_CR71","unstructured":"Translating Emergency Knowledge for Kids EIaICTaE. EIIC-TREKK Pediatric Status Epilepticus Algorithm. 2022 [accessed 02\/13\/2023]; https:\/\/emscimprovement.center\/education-and-resources\/peak\/peak-status-epilepticus\/trekk-eiic-pediatric-status-epilepticus-practice-guideline\/."}],"container-title":["CNS Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-023-01049-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40263-023-01049-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-023-01049-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,2]],"date-time":"2024-11-02T05:56:26Z","timestamp":1730526986000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40263-023-01049-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11]]},"references-count":71,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2023,11]]}},"alternative-id":["1049"],"URL":"https:\/\/doi.org\/10.1007\/s40263-023-01049-w","relation":{},"ISSN":["1172-7047","1179-1934"],"issn-type":[{"value":"1172-7047","type":"print"},{"value":"1179-1934","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11]]},"assertion":[{"value":"25 October 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 November 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"There is no funding to report.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"L. Purwien, L.M. Willems, M. Merker, and M. Czabanka do not report competing interests. S. Schubert-Bast reports personal fees from Eisai, Desitin Pharma, GW Pharmaceuticals, Ethypharm, UCB, and Zogenix. M. Kieslich reports personal fees from Desitin Pharma and Eisai GmbH. F. Rosenow reports personal fees from Angelini Pharma, Arvelle Therapeutics, Desitin Arzneimittel, Eisai GmbH, GW Pharmaceuticals, Jazz Pharmaceuticals, Roche Pharma, and UCB and grants from the Detlev-Wrobel-Fonds for Epilepsy Research, the CHAJA-Foundation, the Deutsche Forschungsgemeinschaft, the LOEWE Programme of the State of Hesse, and the European Union. A. Strzelczyk reports personal fees and grants from Angelini Pharma (Arvelle),\u00a0Biocodex, Desitin Arzneimittel, Eisai, Jazz (GW) Pharmaceuticals, Marinus Pharma, Precisis, Takeda, UCB Pharma (Zogenix), and UNEEG Medical. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or conflict with the subject matter or materials discussed in this manuscript apart from those disclosed.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"This study was approved by the Ethics Advisory Board of Goethe University (Frankfurt am Main, Germany) before it was conducted (reference number 20-951).","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable due to retrospective nature of the study.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"All authors approved the final manuscript for submission.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The datasets generated and\/or analyzed during this study are available from the corresponding author upon reasonable request.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"A. Strzelczyk conceived the idea for the study, was responsible for the data collection, and developed the idea for the analysis. L. Purwien, S. Schubert-Bast, and A. Strzelczyk collected the data. A. Strzelczyk, L.M. Willems, and L. Purwien processed the data and performed the statistical analyses. L.M. Willems created the figures. L. Purwien and A. Strzelczyk drafted the initial manuscript. All authors wrote, edited, and significantly contributed to the final manuscript.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}